CAMBRIDGE, Mass. – September 19, 2019 – Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, today announced that it has appointed Christine Loh, Ph.D., as Senior Vice President, Head of Biology. Across Loh’s wide-ranging industry experience she has driven multiple new therapeutics from early discovery to entry into the clinic, most recently as Vice President of Translational Medicine at Kymera Therapeutics.
“Christine has a track record of strategically advancing research programs and building teams to deliver new medicines to patients, including in oncology and immunology which are part of our core research focus at Nimbus,” said Peter Tummino, Ph.D., Chief Scientific Officer at Nimbus. “We are thrilled that Christine will be joining the Nimbus team at a time of exciting pipeline progress.”
As Vice President of Translational Medicine at Kymera Therapeutics, Loh facilitated biomarker strategy, patient selection and resource-building initiatives to transition pipeline programs into clinical development. Previously, she was the Executive Director of Research at Bioverativ, leading a group focused on hemophilia and sickle cell disease. During that time, Loh also helped progress the spinout of Bioverativ from Biogen, where she had spent five years directing rare disease and immunology research. Loh also has over 20 years of experience as a lead researcher at Sirtris, Pfizer and ICOS Corporation, advancing several programs from concept to IND in autoimmunity, oncology and metabolic disease. She has a B.S. in biochemistry from Wellesley College and a Ph.D. in immunology from the Division of Medical Sciences at Harvard University.
“Nimbus’ structure-based drug discovery capabilities are second to none, and the company’s suite of well-validated targets provides valuable opportunities to develop novel therapeutic agents,” said Loh. “I am delighted to join this team and look forward to guiding the biology organization through a new and exciting period of growth.”
About Nimbus Therapeutics
Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Massachusetts (USA). Nimbus is pioneering the application of highly advanced computational technologies to the design and development of novel treatments for substantial and underserved human diseases. The company’s focus on metabolic diseases, cancer and immune-inflammatory disorders reflects the mechanistic relationship between these disorders, and Nimbus’ ability to rapidly tackle well-validated targets as well as those that have proven intractable to others. The company’s LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. To learn more, please visit www.nimbustx.com.
Lisa Raffensperger, (617) 903-8783
Ten Bridge Communications